$TNON
Tenon Medical, Inc. Stock $tnon

$tnon Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028010 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$719.0K	$808.0K	$2.928M
YoY Change	66.05%	191.7%	323.73%
Cost Of Revenue	$249.0K	$249.0K	$1.687M
YoY Change	-48.13%	-48.55%	26.65%
Gross Profit	$470.0K	$559.0K	$1.241M
YoY Change	-1100.0%	-370.05%	-293.6%
Gross Profit Margin	65.37%	69.18%	42.38%
Selling, General & Admin	$3.307M	$3.009M	$13.81M
YoY Change	-17.43%	-56.45%	-9.51%
% of Gross Profit	703.62%	538.28%	1112.41%
Research & Development	$669.0K	$691.0K	$3.163M
YoY Change	-19.78%	-14.9%	11.85%
% of Gross Profit	142.34%	123.61%	254.88%
Depreciation & Amortization	$100.0K	$93.00K	$199.0K
YoY Change	300.0%	272.0%	155.13%
% of Gross Profit	21.28%	16.64%	16.04%
Operating Expenses	$3.976M	$3.700M	$16.97M
YoY Change	-17.83%	-52.08%	-6.17%
Operating Profit	-$3.506M	-$3.141M	-$15.73M
YoY Change	-28.24%	-60.38%	-16.01%
Interest Expense	$34.00K	$7.000K	$146.0K
YoY Change	-39.29%	-91.25%	-183.91%
% of Operating Profit
Other Income/Expense, Net	-$70.00K	$0.00	$0.00
YoY Change	-225.0%	-100.0%	-100.0%
Pretax Income	-$3.576M	-$3.134M	-$15.58M
YoY Change	-25.96%	-60.35%	-17.63%
Income Tax
% Of Pretax Income
Net Earnings	-$3.576M	-$3.134M	-$15.58M
YoY Change	-25.96%	-60.35%	-17.63%
Net Earnings / Revenue	-497.36%	-387.87%	-532.14%
Basic Earnings Per Share	-$1.25		-$8.59
Diluted Earnings Per Share	-$1.25	-$1.24	-$8.59
COMMON SHARES
Basic Shares Outstanding	3.727M shares	2.471M shares	1.814K shares
Diluted Shares Outstanding	2.853K shares		1.814K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.388M	$2.428M	$2.428M
YoY Change	-10.74%	-71.67%	-71.67%
Cash & Equivalents	$4.388M	$2.428M	$2.428M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$360.0K	$389.0K	$389.0K
YoY Change	86.53%	190.3%	190.3%
Inventory	$632.0K	$554.0K	$554.0K
Prepaid Expenses	$360.0K	$389.0K
Receivables	$571.0K	$518.0K	$518.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.951M	$3.889M	$3.889M
YoY Change	1.88%	-58.39%	-58.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$993.0K	$1.607M	$1.607M
YoY Change	16.55%	102.65%	-3.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$490.0K	$849.0K	$849.0K
YoY Change	315.25%	1017.11%	1017.11%
Total Long-Term Assets	$2.069M	$2.456M	$2.456M
YoY Change	15.72%	40.99%	40.99%
TOTAL ASSETS
Total Short-Term Assets	$5.951M	$3.889M	$3.889M
Total Long-Term Assets	$2.069M	$2.456M	$2.456M
Total Assets	$8.020M	$6.345M	$6.345M
YoY Change	5.13%	-42.78%	-42.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$266.0K	$433.0K	$433.0K
YoY Change	-71.34%	-21.27%	-21.27%
Accrued Expenses	$941.0K	$1.534M	$1.534M
YoY Change	77.55%	113.95%	-22.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.173M	$1.173M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.262M	$3.140M	$3.140M
YoY Change	-17.81%	24.11%	24.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.134M	$2.427M	$2.427M
YoY Change	-11.19%	5.2%	5.2%
Total Long-Term Liabilities	$2.134M	$2.427M	$2.427M
YoY Change	-11.19%	5.2%	5.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.262M	$3.140M	$3.140M
Total Long-Term Liabilities	$2.134M	$2.427M	$2.427M
Total Liabilities	$4.396M	$5.567M	$5.567M
YoY Change	-14.72%	15.09%	15.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.65M	-$55.07M
YoY Change	32.32%	39.45%
Common Stock	$58.97M	$55.90M
YoY Change	536018.18%	508054.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.624M	$778.0K	$778.0K
YoY Change
Total Liabilities & Shareholders Equity	$8.020M	$6.345M	$6.345M
YoY Change	5.13%	-42.78%	-42.78%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.576M	-$3.134M	-$15.58M
YoY Change	-25.96%	-60.35%	-17.63%
Depreciation, Depletion And Amortization	$100.0K	$93.00K	$199.0K
YoY Change	300.0%	272.0%	155.13%
Cash From Operating Activities	-$2.338M	-$2.278M	-$12.18M
YoY Change	-34.62%	-32.7%	1.31%
INVESTING ACTIVITIES
Capital Expenditures	$119.0K	$92.00K	$361.0K
YoY Change	41.67%	-84.69%	-57.38%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$6.503M
YoY Change	-100.0%	-100.0%	-419.24%
Cash From Investing Activities	-$119.0K	-$92.00K	$6.142M
YoY Change	-102.55%	-103.93%	-312.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.561M
YoY Change			-60.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.371M	1.371M	6.302M
YoY Change	-10507.14%	-5584.0%	-55.35%
NET CHANGE
Cash From Operating Activities	-$2.338M	-2.278M	-12.18M
Cash From Investing Activities	-$119.0K	-92.00K	6.142M
Cash From Financing Activities	$4.371M	1.371M	6.302M
Net Change In Cash	$1.960M	-999.0K	261.0K
YoY Change	86.67%	-6.72%	-133.12%
FREE CASH FLOW
Cash From Operating Activities	-$2.338M	-$2.278M	-$12.18M
Capital Expenditures	$119.0K	$92.00K	$361.0K
Free Cash Flow	-$2.457M	-$2.370M	-$12.54M
YoY Change	-32.87%	-40.54%	-2.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.59
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41364
CY2023	dei	Entity Registrant Name EntityRegistrantName	TENON MEDICAL, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5574718
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	104 Cooper Court
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Gatos
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95032
CY2023	dei	City Area Code CityAreaCode	(408)
CY2023	dei	Local Phone Number LocalPhoneNumber	649-5760
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4891898	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3726974	shares
CY2023	dei	Auditor Firm AuditorFirmId	32
CY2023	dei	Auditor Name AuditorName	Armanino LLP
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2428000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2129000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	6441000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	518000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	228000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	554000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	415000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	389000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	134000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3889000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1687000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9347000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	961000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	793000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	51000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	873000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	798000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	25000	usd
CY2023Q4	us-gaap	Assets Assets	6345000	usd
CY2022Q4	us-gaap	Assets Assets	11089000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	433000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	550000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	808000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	717000	usd
CY2023Q4	tnon	Accrued Commissions Current AccruedCommissionsCurrent	470000	usd
CY2022Q4	tnon	Accrued Commissions Current AccruedCommissionsCurrent	1035000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	228000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	77000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1173000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3140000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2530000	usd
CY2023Q4	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1999000	usd
CY2022Q4	tnon	Accrued Commissions Noncurrent AccruedCommissionsNoncurrent	1624000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	683000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5567000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4837000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2600311	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2600311	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1123680	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1123680	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55894000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45843000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55073000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39492000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-46000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6252000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6345000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11089000	usd
CY2023	us-gaap	Revenues Revenues	2928000	usd
CY2022	us-gaap	Revenues Revenues	691000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1332000	usd
CY2023	us-gaap	Gross Profit GrossProfit	1241000	usd
CY2022	us-gaap	Gross Profit GrossProfit	-641000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3163000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2828000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6778000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7833000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7027000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7423000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	16968000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	18084000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15727000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18725000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	167000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	180000	usd
CY2023	us-gaap	Interest Expense InterestExpense	21000	usd
CY2022	us-gaap	Interest Expense InterestExpense	354000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	146000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-192000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15581000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18917000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.59
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.62
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1814	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	801	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15581000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18917000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	16000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-16000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	38000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15527000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18926000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-20552000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2897000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	13765000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	-12367000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1272000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13868000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1561000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18917000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6252000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4145000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4808000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	495000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	289000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	258000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	58000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	54000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15581000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	778000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15581000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18917000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	362000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4145000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2897000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1561000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	199000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-77000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	227000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	211000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	290000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	152000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	139000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	227000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	301000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-117000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	72000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-99000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2288000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-227000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-202000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12183000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12025000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	6996000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	8079000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	493000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10116000	usd
CY2023	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	361000	usd
CY2022	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	847000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6142000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2884000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4808000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14139000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	495000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1250000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	258000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	509000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	25000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6302000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14114000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	299000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-788000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2129000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2917000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2428000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2129000	usd
CY2023Q4	us-gaap	Cash Cash	2428000	usd
CY2022Q4	us-gaap	Cash Cash	480000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1649000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	13639000	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	13868000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. Organization and Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Nature of operations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tenon Medical, Inc. (the “Company”) was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed The Catamaran™ SI Joint Fusion System (“the Catamaran System”) that offers a novel, less invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the U.S. market. Since the national launch of the Catamaran System in October 2022, the Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Basis of consolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The condensed financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects.</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Use of estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, obsolescence of inventory, the fair value of accrued commissions and stock-based compensation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p>
CY2022Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1	shares
CY2023	tnon	Cash And Cash Equivalents Criteria Maturity Period CashAndCashEquivalentsCriteriaMaturityPeriod	P90D
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P12Y
CY2021Q2	tnon	Percentage Of Weightage Given To Market Approach PercentageOfWeightageGivenToMarketApproach	1	pure
CY2021Q2	tnon	Discount Rate Percentage DiscountRatePercentage	0.224	pure
CY2021Q2	tnon	Percentage Of Adjustments Of Risk Reduction PercentageOfAdjustmentsOfRiskReduction	0.02	pure
CY2021Q3	tnon	Percentage Of Weightage Given To Market Approach PercentageOfWeightageGivenToMarketApproach	1	pure
CY2021Q3	tnon	Discount Rate Percentage DiscountRatePercentage	0.32	pure
CY2021Q3	tnon	Percentage Of Adjustments Of Risk Reduction PercentageOfAdjustmentsOfRiskReduction	0.05	pure
CY2021Q4	tnon	Discount Rate Percentage DiscountRatePercentage	0.272	pure
CY2021Q4	tnon	Percentage Of Adjustments Of Risk Reduction PercentageOfAdjustmentsOfRiskReduction	0.05	pure
CY2018	tnon	Percentage Of Weightage In Discounted Cash Flow PercentageOfWeightageInDiscountedCashFlow	1	pure
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	873000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	273000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	961000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	793000	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	193000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	78000	usd
CY2019	tnon	Percentage Of Weightage In Discounted Cash Flow PercentageOfWeightageInDiscountedCashFlow	1	pure
CY2020	tnon	Percentage Of Weightage In Discounted Cash Flow PercentageOfWeightageInDiscountedCashFlow	1	pure
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2106605	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	231347	shares
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	167000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	180000	usd
CY2023Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	8000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	13000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	9000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	532000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	406000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	554000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	415000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1234000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	334000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	452000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	474000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	808000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	717000	usd
CY2023	tnon	Term Of Warrants Expire TermOfWarrantsExpire	P5Y
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	292000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	292000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	873000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	228000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	683000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	684000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	911000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	302000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	310000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	144000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	756000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	684000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	293000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	284000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	tnon	Equity Ownership Percentage EquityOwnershipPercentage	0.03	pure
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1000000	shares
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4808	usd
CY2023Q2	tnon	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.146
CY2023Q2	tnon	Aggregate Gross Sales Price AggregateGrossSalesPrice	5500000	usd
CY2023Q2	tnon	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.03	pure
CY2023	tnon	Aggregate Net Proceeds AggregateNetProceeds	495	usd
CY2023	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	(i) up to 12,500 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $15.00 per share and (ii) up to 15,000 shares of common stock, if the closing sale price of its common stock on Nasdaq on such business day is at least $25.00 per share
CY2023	tnon	Purchase Exceed Amount PurchaseExceedAmount	500000	usd
CY2023	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	100000	shares
CY2023	tnon	Percentage Of Outstanding Shares PercentageOfOutstandingShares	0.0499	pure
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.9
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	tnon	Share Based Compensation Expenses Not Yet Unvested Options ShareBasedCompensationExpensesNotYetUnvestedOptions	414	usd
CY2023	tnon	Share Based Compensation Unvested Options Weighted Average Remaining Contractual Term ShareBasedCompensationUnvestedOptionsWeightedAverageRemainingContractualTerm	P0Y11M26D
CY2023	tnon	Share Based Compensation Expenses Not Yet Restricted Stock Units ShareBasedCompensationExpensesNotYetRestrictedStockUnits	4773	usd
CY2023	tnon	Share Based Compensation Restricted Stock Units Weighted Average Remaining Contractual Term ShareBasedCompensationRestrictedStockUnitsWeightedAverageRemainingContractualTerm	P1Y4M24D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4145000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2897000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2000000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.6
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2023	tnon	Class Of Warrants Of Rights Grant Date Fair Value Of Warrants ClassOfWarrantsOfRightsGrantDateFairValueOfWarrants	3164
CY2023	tnon	Fair Value Of Offering Warrant FairValueOfOfferingWarrant	1.58
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3
CY2023	tnon	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Daily Return Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDailyReturnRate	0.0518	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1	pure
CY2023	tnon	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Standarddeviation ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStandarddeviation	0.063	pure
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2560000	usd
CY2023	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	592000	usd
CY2023	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	409000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2377000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15570000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18886000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-11000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-30000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-15581000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-18916000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	33644	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	-0.07	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.03	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.25	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.27	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9504000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7001000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	220000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	109000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	52000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	111000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	126000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1802000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	843000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	220000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	244000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	188000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	254000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	514000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	274000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12611000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8851000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12433000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8564000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	178000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	287000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Regulatory Assets DeferredTaxLiabilitiesRegulatoryAssets	44000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	178000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	243000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	178000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	287000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	33866	usd
CY2023Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	222	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	32147	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1378	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	214	usd
CY2023	tnon	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	P2041Y
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	36000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	26000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	38000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1.5125
CY2023	tnon	Number Of Trading Days NumberOfTradingDays	10	pure
CY2023	tnon	Percentage Of Volumeweighted Average Price PercentageOfVolumeweightedAveragePrice	2.50	pure
CY2023Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	50	pure
CY2023	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	2250000	usd
CY2023	tnon	Percentage Of Shares Issued To Shareholders PercentageOfSharesIssuedToShareholders	0.50	pure
CY2023	tnon	Liquidation Preference Payable On Deemed Liquidation LiquidationPreferencePayableOnDeemedLiquidation	1.10	pure
CY2023	us-gaap	Credit Derivative Liquidation Proceeds Percentage CreditDerivativeLiquidationProceedsPercentage	0.10	pure
CY2023	tnon	Indebtedness Excess Cost IndebtednessExcessCost	1000000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-23.62
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1814	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	801	shares
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Interest Paid Capitalized InterestPaidCapitalized		usd
CY2022	us-gaap	Interest Paid Capitalized InterestPaidCapitalized		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2021Q4	tnon	Percentage Of Weightage Given To Market Approach PercentageOfWeightageGivenToMarketApproach		pure
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions		usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001560293

Files In Submission

Name	View Source	Status
0001213900-24-028010-index-headers.html	Edgar Link	pending
0001213900-24-028010-index.html	Edgar Link	pending
0001213900-24-028010.txt	Edgar Link	pending
0001213900-24-028010-xbrl.zip	Edgar Link	pending
ea0201083-10k_tenonmed.htm	Edgar Link	pending
ea020108301ex10-10_tenonmed.htm	Edgar Link	pending
ea020108301ex10-11_tenonmed.htm	Edgar Link	pending
ea020108301ex10-7_tenonmed.htm	Edgar Link	pending
ea020108301ex10-8_tenonmed.htm	Edgar Link	pending
ea020108301ex19-1_tenonmed.htm	Edgar Link	pending
ea020108301ex23-1_tenonmed.htm	Edgar Link	pending
ea020108301ex23-2_tenonmed.htm	Edgar Link	pending
ea020108301ex31-1_tenonmed.htm	Edgar Link	pending
ea020108301ex31-2_tenonmed.htm	Edgar Link	pending
ea020108301ex32-1_tenonmed.htm	Edgar Link	pending
ea020108301ex32-2_tenonmed.htm	Edgar Link	pending
ea020108301ex4-5_tenonmed.htm	Edgar Link	pending
ea020108301ex97-1_tenonmed.htm	Edgar Link	pending
ex10-11_001.jpg	Edgar Link	pending
ea0201083-10k_tenonmed_htm.xml	Edgar Link	completed
ex10-11_002.jpg	Edgar Link	pending
ex10-11_003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tnon-20231231.xsd	Edgar Link	pending
tnon-20231231_def.xml	Edgar Link	unprocessable
tnon-20231231_lab.xml	Edgar Link	unprocessable
tnon-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tnon-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNON
Tenon Medical, Inc. Stock $tnon

2024 Q1 Form 10-K Financial Statement

#000121390024028010 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON Tenon Medical, Inc. Stock $tnon

2024 Q1 Form 10-K Financial Statement

#000121390024028010 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNON
Tenon Medical, Inc. Stock $tnon